Research - 20.05.2021 - 00:00
20 May 2021. Currently there is a shortage of COVID-19 vaccines. The 1.73 billion doses of vaccine produced to date pales when compared to the 10.82 billion doses needed to inoculate 75% of the world’s population aged 5 or over. The shortage is acute in many developing countries that have been unable to secure vaccine supplies—hence legitimate concerns about the equitable access. That new variants develop among the uninoculated which then spread across borders is a reminder that a global perspective on vaccine production and distribution is required.
The private sector is ramping up fast COVID-19 vaccine production, thereby narrowing the gap between vaccine supply and demand. The purpose of this note is to report the latest estimates of how much of the vaccine shortage will be eliminated this year, given what is known today about existing vaccine production capacity, announced capacity expansion this year, and sobering lessons learned from attempts to boost production during the first five months of this year. The projections reported here do not include any extra production that might result from the adoption of a TRIPS waiver at the World Trade Organization.
How good are forecasts?
Inevitably, any forward-looking exercise like this involves making forecasts—details of which can be found in the box below. How good are previous forecasts using this approach? Figure 1 shows the total production levels forecasted in February 2021, the observed outcomes, and contrasts them to the vaccine manufacturers’ projections. The latter were way off. However, Airfinity’s forecasts closely track the substantial vaccine production increases observed in March and April 2021. The average percentage forecast error fell from 20.1% in March to just 9.8% in April.
Using the same method, and taking account of the fact that 18 vaccines are in phase III trials and given what is known about the likelihood of their approval and related production plans, it is possible to project out COVID-19 vaccine production through to the end of 2021 (see Figure 2). By the end of December 2021, the total number of doses produced is projected to be 11.14 billion, exceeding the 10.82 billion doses needed.
Current vaccine shortage can be eliminated this year
Production in the third quarter of 2021 is expected to be in excess of 3 billion doses, whereas in the fourth quarter production is expected to reach just under 5 billion doses. Should these forecasts come to pass, enough vaccine will have been produced this year to reach herd immunity worldwide. Booster shots would add to demand—but the first round of inoculation would not be held back on account of limited production. These findings imply the current vaccine shortage can be eliminated this year.
Production of three vaccines is forecast to dominate global supply this year: 2.47 billion doses of BNT162b2 vaccine (produced by BioNTech and Pfizer), 1.96 billion doses of AZD1222 vaccine (produced by Astra-Zeneca), and 1.35 billion doses of Sinovac vaccine. The projected production of 11.14 billion doses of COVID-19 vaccine is half (50.5%) of the total company stated production targets for this year (22.03 billion doses), indicating further potential upside. The key takeaway is that every step should be taken to facilitate the ramp up production using current vaccine production capacity. Adding to that capacity is probably not the first order priority.
Given what is known about the delivery schedule of vaccines, some jurisdictions will have accumulated significant amounts of surplus vaccines by the end of this year. The largest surplus will be held by the European Union (885 million doses), followed by the United States (539 million doses), Japan (300 million doses), the United Kingdom (297 million doses), Brazil (177 million doses), and Canada (175 million doses). Together, these six jurisdictions will account for 89.7% of the likely global surplus of COVID-19 vaccines at the end of this year, which is estimated to exceed 2.6 billion doses.
Critical importance of distributing the huge number of vaccines
To put this surplus in perspective, with the expected production and delivery schedule, COVAX is expected to receive 1.11 billion doses by the end of this year. Sharing surplus vaccines with COVAX would more than triple the vaccines available to that organisation this year. This highlights the critical importance of distributing worldwide the huge number of vaccines likely to be produced this year.
What could go wrong? Apart from vaccine hoarding by governments and the risks created by policies that disrupt relevant international supply chains, concerns have been raised by sectoral experts about possible shortages of certain COVID-19 vaccine ingredients and medical items needed to distribute vaccines. Examples of bottlenecks have been mentioned in recent press reports, however we are aware of no evidence of a broad-based threat to the projected vaccine production ramp up. Still, this matter requires careful monitoring and reinforces recent calls for greater transparency along the entire vaccine production and distribution chain.
How Airfinity’s production projections are made
Data was collected on stated annual production capacity for each vaccine manufacturing facility globally, which is used to build a deterministic model. The three main inputs for each facility are company stated production, real observed production, and assumptions on scale-up time. Airfinity tracks the production and deliveries of vaccine doses by each site where vaccine manufacture is underway. Start dates for the bulk production at sites yet to come online are estimated based on when the relevant vaccine is expected to publish phase 3 efficacy data and be approved. A production facility usually takes 3-4 months to reach capacity, an assumption based on expert insight. When available, a production forecast is matched up to observed data and any discrepancies result in adjustments to the forecasting model. This approach generates forecast over time of the total number of doses produced for each vaccine across the globe.
Simon J. Evenett is Professor of Economics, University of St.Gallen Switzerland & Founder, St.Gallen Endowment for Prosperity Through Trade. Matt Linley is Senior Analyst, Airfinity.
Image: Adobe Stock / James Thew
More articles from the same category
A new whitepaper, with the participation of researchers from HSG, reveals how Swiss households are adopting plant-based diets. The study reveals that…
For the first time, the School of Medicine and the Cancer League of Eastern Switzerland have formed a research collaboration. Data from the "donna"…
The Canton of St.Gallen wants to become more attractive for young companies. HSG experts were significantly involved in the development of a cantonal…
The Swiss manufacturing industry is experiencing a trend of reshoring production facilities to Switzerland. These and other insights were provided by…
Discover our special topics